Galderma Laboratories announced the completion of two independent Phase 3 clinical trials that evaluated the safety and efficacy of CD07805/47, a proprietary topical gel under investigation in patients with moderate to severe facial erythema of rosacea. The trials examined the safety and efficacy of CD07805/47 applied topically (vs. vehicle control). The company has not released figures, but reported that the findings from each of these trials confirmed results observed in previous studies.